When paired with selective activation of CB1R-which directly counters AD-related synaptic and inflammatory deficits-and careful modulation of CB2R to curb excessive inflammation, this dual strategy addresses the major pathological hallmarks of AD: cognitive decline, neuroinflammation, and synaptic dysfunction. This evidence concerns the gene CNR1 and Mental deterioration.